var data={"title":"Glyburide (glibenclamide): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Glyburide (glibenclamide): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6273?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=glyburide-glibenclamide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Glyburide (glibenclamide): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176698\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Diabeta [DSC];</li>\n      <li>Glynase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176699\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>DiaBeta;</li>\n      <li>Euglucon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176748\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidiabetic Agent, Sulfonylurea</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176703\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Micronized glyburide tablets are <b>not</b> bioequivalent to conventional glyburide tablets; retitration should occur if patients are being transferred to a different glyburide formulation (eg, micronized-to-conventional or vice versa) or from other hypoglycemic agents. When converting to glyburide from other oral hypoglycemic agents with a long half-life (eg, chlorpropamide), observe patient carefully for 2 weeks due to overlapping hypoglycemic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Diabetes mellitus, type 2:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Conventional tablets (Dia&beta;eta):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 2.5 to 5 mg daily, administered with breakfast or the first main meal of the day. In patients who are more sensitive to hypoglycemic drugs, start at 1.25 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adjustment: Increase in increments of no more than 2.5 mg daily at weekly intervals based on the patient's blood glucose response</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: 1.25 to 20 mg daily given as single or divided doses. Some patients (especially those receiving &gt;10 mg daily) may have a more satisfactory response with twice-daily dosing. Maximum: 20 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Micronized tablets (Glynase PresTab):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 1.5 to 3 mg daily, administered with breakfast or the first main meal of the day. In patients who are more sensitive to hypoglycemic drugs, start at 0.75 mg daily. Increase in increments of no more than 1.5 mg daily in weekly intervals based on the patient's blood glucose response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: 0.75 to 12 mg daily given as a single dose or in divided doses. Some patients (especially those receiving &gt;6 mg daily) may have a more satisfactory response with twice-daily dosing. Maximum: 12 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Management of noninsulin-dependent diabetes mellitus in patients previously maintained on insulin:</b> Oral: Initial dosage dependent upon current insulin dosage, see table.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Dose Conversion: Insulin to Glyburide</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Current Daily Insulin Dosage</p>\n            <p style=\"text-indent:0em;\">(units daily)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Initial Glyburide Dosage</p>\n            <p style=\"text-indent:0em;\">\n              <i>Conventional Formulation</i></p>\n            <p style=\"text-indent:0em;\">(mg daily)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Initial Glyburide Dosage</p>\n            <p style=\"text-indent:0em;\">\n              <i>Micronized Formulation</i></p>\n            <p style=\"text-indent:0em;\">(mg daily)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Insulin Dosage Change</p>\n            <p style=\"text-indent:0em;\">(after glyburide started)</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;20</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5-5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.5-3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Discontinue</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20-40</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Discontinue</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;40</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5</p>\n            <p style=\"text-indent:0em;\">(increase in increments of 1.25-2.5 mg every 2-10 days)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3</p>\n            <p style=\"text-indent:0em;\">(increase in increments of 0.75-1.5 mg every 2-10 days)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Reduce insulin dosage by 50% (gradually taper off insulin as glyburide dosage increased)</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990695\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer's labeling; however, glyburide is generally not recommended in chronic kidney disease; if sulfonylurea therapy is needed, other agents are preferred (ADA [Tuttle 2014]; Alsahli 2015; KDOQI [Nelson 2012]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988016\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, use conservative initial and maintenance doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176704\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid use (Beers Criteria [AGS 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manufacturer&rsquo;s recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conventional tablets (Dia&beta;eta): Oral: Initial: 1.25 mg daily. Conservative initial and maintenance doses are recommended to avoid hypoglycemic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Micronized tablets (Glynase PresTab): Initial: 0.75 mg daily. Conservative initial and maintenance doses are recommended to avoid hypoglycemic reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176673\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diabeta: 1.25 mg [DSC], 2.5 mg [DSC], 5 mg [DSC] [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glynase: 1.5 mg, 3 mg, 6 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1.25 mg, 1.5 mg, 2.5 mg, 3 mg, 5 mg, 6 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176659\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22123827\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Micronized formulation: Glynase</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176678\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with meals at the same time each day (twice-daily dosing may be beneficial if conventional glyburide doses are &gt;10 mg or micronized glyburide doses are &gt;6 mg). Patients that are NPO or require decreased caloric intake may need doses held to avoid hypoglycemia. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176677\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetes mellitus, type 2:</b> Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725974\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Gestational diabetes mellitus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176756\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">GlyBURIDE may be confused with glipiZIDE, Glucotrol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dia&beta;eta may be confused with Zebeta</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Micronase may be confused with Microzide</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Glyburide is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its higher risk of severe prolonged hypoglycemia in older adults (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Glyburide is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176666\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Epigastric fullness (&le;2%), heartburn (&le;2%), nausea (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (2%; including erythema, maculopapular rash, morbilliform rash, pruritus, urticaria)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Disulfiram-like reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypoglycemia, hyponatremia, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Diuresis (minor)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemolytic anemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Cholestatic jaundice, hepatic failure, hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Accommodation disturbance, angioedema, arthralgia, blurred vision, bullous rash, erythema multiforme, exfoliative dermatitis, increased serum transaminases, myalgia, vasculitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176681\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to glyburide or any component of the formulation; type 1 diabetes mellitus or diabetic ketoacidosis, with or without coma; concomitant use with bosentan.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to any sulfonylurea or sulfonamide; diabetic precoma or coma, stress conditions (eg, severe infections, trauma, surgery); liver disease or frank jaundice; renal impairment; pregnancy; breastfeeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for sulfonylureas is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176663\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse reactions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular mortality: Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS) have not supported an association.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished or debilitated patients, and in patients with severe renal and hepatic impairment, adrenal and/or pituitary insufficiency; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfonamide (&ldquo;sulfa&rdquo;) allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glucose-6-phosphate dehydrogenase deficiency: Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: The metabolism and excretion of glyburide may be slowed in patients with renal impairment and its active metabolites may accumulate in advanced renal insufficiency (Snyder 2004). If hypoglycemia should occur, it may be prolonged. Use of glyburide is generally not recommended in chronic kidney disease (ADA [Tuttle 2014]; Alsahli 2015; KDOQI [Nelson 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Glyburide is a longer-duration sulfonylurea; avoid use in older adults due to potential for severe hypoglycemia (Beers Criteria [AGS 2015]). If sulfonylureas are used, those of shorter duration (eg, glipizide) are preferred (ADA 2018b).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glyburide tablet formulations: <i>Micronized</i> glyburide tablets are <b>not</b> bioequivalent to <i>conventional </i>glyburide tablets; retitration should occur if patients are being transferred to a different glyburide formulation (eg, micronized-to-conventional or vice versa) or from other hypoglycemic agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not for use in patients with diabetic ketoacidosis (DKA) or patients with type 1 diabetes mellitus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary failure: Loss of efficacy may be observed following prolonged use as a result of the progression of type 2 diabetes mellitus which results in continued beta cell destruction. In patients who were previously responding to sulfonylurea therapy, consider additional factors which may be contributing to decreased efficacy (eg, inappropriate dose, nonadherence to diet and exercise regimen). If no contributing factors can be identified, consider discontinuing use of the sulfonylurea due to secondary failure of treatment. Additional antidiabetic therapy (eg, insulin) will be required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176743\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C9 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176668\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8494&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: GlyBURIDE may enhance the hepatotoxic effect of Bosentan. GlyBURIDE may decrease the serum concentration of Bosentan. Bosentan may decrease the serum concentration of GlyBURIDE. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbocisteine: Sulfonylureas may enhance the adverse/toxic effect of Carbocisteine. Specifically, sulfonylureas may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Concurrent use of ceritinib with a CYP2C9 substrate that has a narrow therapeutic index (eg, warfarin, phenytoin) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May decrease the metabolism of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May increase the serum concentration of GlyBURIDE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colesevelam: May decrease the serum concentration of GlyBURIDE. Management: Administer glyburide at least 4 hours prior to colesevelam.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclic Antidepressants: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May diminish the therapeutic effect of GlyBURIDE. GlyBURIDE may increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Sulfonylureas. Management: Seek alternatives when possible.  If used together, monitor closely for increased effects of sulfonylureas if fluconazole is initiated/dose increased, or decreased effects if fluconazole is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving both basal insulin and a sulfonylurea.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: May increase the serum concentration of GlyBURIDE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metreleptin: May enhance the hypoglycemic effect of Sulfonylureas. Management: Sulfonylurea dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miconazole (Oral): May enhance the hypoglycemic effect of Sulfonylureas. Miconazole (Oral) may increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitiglinide: May enhance the adverse/toxic effect of Sulfonylureas.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RaNITIdine: May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Sulfonylureas. Management: Seek alternatives to these combinations when possible.  Monitor closely for diminished therapeutic effects of sulfonylureas if rifampin is initiated/dose increased, or enhanced effects if rifampin is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonamide Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazolidinediones: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose adjustments in patients taking thiazolidinediones and monitor for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24257169\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Ethanol may cause rare disulfiram reactions. Management: Monitor patients.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176684\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Glyburide crosses the placenta. Some pharmacokinetic properties of glyburide may change during pregnancy (Hebert 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Severe hypoglycemia lasting 4 to 10 days has been noted in infants born to mothers taking a sulfonylurea at the time of delivery. Additional adverse maternal and fetal events have been noted in some studies and may be influenced by maternal glycemic control and/or differences in study design (Bertini 2005; Ekpebegh 2007; Joy 2012; Langer 2000; Langer 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2018c; Kitzmiller 2008; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ACOG 2013; ADA 2018c; Blumer 2013; Kitzmiller 2008).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Agents other than glyburide are currently recommended to treat diabetes in pregnant women (ADA 2018c). According to the manufacturer, if glyburide is used during pregnancy, it should be discontinued at least 2 weeks before the expected delivery date.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699343\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glyburide may be present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The relative infant dose (RID) of glyburide is 0.08% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 90 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The RID of glyburide was calculated using a milk concentration of 7.3 ng/mL, providing an estimated daily infant dose via breast milk of 0.001 mg/kg/day. This milk concentration was obtained following maternal administration of very large doses of glyburide (up to 90 mg/day) for the treatment of permanent neonatal diabetes mellitus (PNDM) caused by a KCNJ11 (Kir6.2) mutation throughout pregnancy. Glyburide was also detected in the serum of the breastfeeding infant 6 days after birth (Myngheer 2014). Glyburide was not detected in breast milk following short-term maternal use with standard doses (Feig 2005); however, chronic therapy was not evaluated.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Current guidelines note that breastfeeding is encouraged for all women, including those with diabetes (ACOG 2005; ADA 2018c; Blumer 2013; Metzger 2007). A small snack (such as milk) before breastfeeding may help decrease the risk of hypoglycemia in women with pregestational diabetes (ACOG 2005; Reader 2004).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">According to the manufacturer, due to the potential for hypoglycemia in the breastfeeding infant, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother. However other sources note that glyburide may be used in breastfeeding women (Blumer 2013; Metzger 2007). The World Health Organization considers glyburide compatible with breastfeeding if the infant is monitored for hypoglycemia (WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176685\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Should be taken with meals at the same time each day (twice-daily dosing may be beneficial if conventional glyburide doses are &gt;10 mg or micronized glyburide doses are &gt;6 mg). Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176671\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs and symptoms of hypoglycemia, urine glucose test, fasting blood glucose, hemoglobin A<sub>1c</sub> (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2018a])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176674\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for glycemic control in nonpregnant adults with diabetes (ADA 2018a):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 80 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak postprandial capillary blood glucose: &lt;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in older adults (&ge;65 years) with diabetes (ADA 2018b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (healthy); &lt;8% (complex/intermediate health); &lt;8.5% (very complex/poor health) (individualization may be appropriate based on patient and caregiver preferences)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 90 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime capillary blood glucose: 90 to 150 mg/dL (healthy); 100 to 180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176662\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176680\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Serum insulin levels begin to increase 15-60 minutes after a single dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: &le;24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Significant within 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: Extensive, primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; forms metabolites (weakly active)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Variable among oral dosage forms</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Dia&beta;eta: 10 hours; Glynase PresTab: ~4 hours; may be prolonged with renal or hepatic impairment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Adults: 2-4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (50%) and urine (50%) as metabolites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176683\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (GlyBURIDE Micronized Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (100): $37.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (100): $60.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (100): $107.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (GlyBURIDE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25 mg (100): $27.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $45.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $77.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Glynase Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (100): $214.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (100): $362.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (100): $572.14</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176686\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Allase (PH);</li>\n      <li>Apo-Glibenclamide (NZ);</li>\n      <li>Benclamin (TH);</li>\n      <li>Benil (SG);</li>\n      <li>Betanase (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LK, LY, OM, QA, SA, SY, YE);</li>\n      <li>Betanese 5 (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Bevoren (LU);</li>\n      <li>Brucen (MX);</li>\n      <li>Calabren (CZ);</li>\n      <li>Clamiben (BR);</li>\n      <li>Clamide (HK);</li>\n      <li>Daonil (AE, AR, AU, BD, BE, BF, BH, BJ, BO, BR, CH, CI, CL, CR, CY, DK, DO, EG, ES, ET, FR, GH, GM, GN, GR, GT, HK, HN, HR, ID, IN, IQ, IR, IT, JO, JP, KE, KR, KW, LB, LK, LR, LU, LY, MA, ML, MR, MU, MW, MY, NE, NG, NI, NO, NZ, OM, PA, PH, PT, PY, QA, RU, SA, SC, SD, SG, SL, SN, SV, SY, TH, TN, TR, TW, TZ, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Daosin (BD);</li>\n      <li>Diaben (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Diabenol (TH);</li>\n      <li>Diabesulf (EC);</li>\n      <li>Diabetin (TW);</li>\n      <li>Dibelet (MY);</li>\n      <li>Dynor (BD);</li>\n      <li>Euclamin (PL);</li>\n      <li>Euglucan (FR);</li>\n      <li>Euglucon (AE, AR, AT, AU, BD, BE, BF, BH, BJ, BO, CH, CI, CO, CY, CZ, DE, EC, EG, ET, FI, GH, GM, GN, GR, HK, HR, IN, IQ, IR, IT, JO, JP, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NZ, OM, PH, PK, PT, PY, QA, RU, SA, SC, SD, SE, SG, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Gilemal (AT, HU);</li>\n      <li>Glamide (TH);</li>\n      <li>Glarin (BD);</li>\n      <li>Gliban (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Glibedal (HR);</li>\n      <li>Gliben (IT, LK);</li>\n      <li>Gliben-CP (HK);</li>\n      <li>Glibenclamid (HR);</li>\n      <li>Glibenclamid Pharmavit (HU);</li>\n      <li>Glibenclamid-ratiopharm (LU);</li>\n      <li>Glibenhexal (LU);</li>\n      <li>Glibesyn (MY, SG, TH);</li>\n      <li>Glibet (IN);</li>\n      <li>Glibetic (IL);</li>\n      <li>Glibetics (LK);</li>\n      <li>Glibil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Glibil-5 (SA);</li>\n      <li>Gliboral (BF, BJ, CI, ET, GH, GM, GN, KE, LB, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Glidiabet (PE);</li>\n      <li>Glihexal (VN);</li>\n      <li>Glimel (AU, HK);</li>\n      <li>Glipiz (LK);</li>\n      <li>Glisulin (KR);</li>\n      <li>Glitisol (ET, MT, TR, ZW);</li>\n      <li>Gluben (IL);</li>\n      <li>Glucobene (HU);</li>\n      <li>Glucolon (ES);</li>\n      <li>Glucomid (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Gluconic (ID);</li>\n      <li>Gluconil (BD);</li>\n      <li>Glucoven (MX);</li>\n      <li>Gluzo (TH);</li>\n      <li>Glycomin (ZA);</li>\n      <li>Glynase (AE, BB, QA);</li>\n      <li>Hemi-Daonil (AR, FR, MA);</li>\n      <li>Hipexal (CL);</li>\n      <li>Lodulce (PH);</li>\n      <li>Maninil (BG, EE, UA);</li>\n      <li>Manoglucon (TH);</li>\n      <li>Melix (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Miglucan (FR);</li>\n      <li>Orabetic (PH);</li>\n      <li>Padonil (ID);</li>\n      <li>Pira (AR);</li>\n      <li>Renabetic (ID);</li>\n      <li>Semi-Daonil (AE, AR, AU, BH, CH, CY, EG, GB, IQ, IR, JO, KW, LB, LY, MA, OM, PT, QA, SA, SY, YE);</li>\n      <li>Semi-Euglucon (AR, AT, AU, NZ);</li>\n      <li>Sentionyl (PH);</li>\n      <li>Sugril (TH);</li>\n      <li>Variglyben (ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al, &ldquo;Intensive Blood Glucose Control and Vascular Outcomes in Patients With Type 2 Diabetes,&rdquo; <i>N Engl J Med</i>, 2008, 358(24):2560-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/18539916/pubmed\" target=\"_blank\" id=\"18539916\">18539916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alsahli M, Gerich JE. Hypoglycemia in Patients with Diabetes and Renal Disease. <i>J Clin Med</i>. 2015;4(5):948-964. doi: 10.3390/jcm4050948.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/26239457/pubmed\" target=\"_blank\" id=\"26239457\">26239457</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins, &quot;Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational Diabetes Mellitus,&quot; <i>Obstet Gynecol</i>, 2005, 105(3):675-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/15738045/pubmed\" target=\"_blank\" id=\"15738045\">15738045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Committee on Practice Bulletins--Obstetrics. Practice Bulletin No. 137: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2013;122(2 Pt 1):406-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/23969827 /pubmed\" target=\"_blank\" id=\"23969827 \">23969827 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222377\"></a>American Diabetes Association (ADA). 6. Glycemic targets: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018a;41(suppl 1):S55-S64. doi: 10.2337/dc18-S006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/29222377/pubmed\" target=\"_blank\" id=\"29222377\">29222377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222382\"></a>American Diabetes Association (ADA). 11. Older adults: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018b;41(suppl 1):S119-S125. doi: 10.2337/dc18-S011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/29222382/pubmed\" target=\"_blank\" id=\"29222382\">29222382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222384\"></a>American Diabetes Association (ADA). 13. Management of diabetes in pregnancy: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018c;41(suppl 1):S137-S143. doi: 10.2337/dc18-S013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/29222384/pubmed\" target=\"_blank\" id=\"29222384\">29222384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25609400\"></a>Balsells M, Garc&iacute;a-Patterson A, Sol&agrave; I, Roqu&eacute; M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. <i>BMJ</i>. 2015;350:h102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/25609400/pubmed\" target=\"_blank\" id=\"25609400\">25609400</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bertini AM, Silva JC, Taborda W, et al, &quot;Perinatal Outcomes and the Use of Oral Hypoglycemic Agents,&quot; <i>J Perinat Med</i>, 2005, 33(6):519-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/16318615/pubmed\" target=\"_blank\" id=\"16318615\">16318615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/24194617 /pubmed\" target=\"_blank\" id=\"24194617 \">24194617 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/15303450/pubmed\" target=\"_blank\" id=\"15303450\">15303450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24807336\"></a>Camelo Castillo W, Boggess K, St&uuml;rmer T, Brookhart MA, Benjamin DK Jr, Jonsson Funk M. Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. <i>Obstet Gynecol</i>. 2014;123(6):1177-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/24807336/pubmed\" target=\"_blank\" id=\"24807336\">24807336</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DiaBeta (glyburide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diabeta (glyburide) [product monograph]. Laval, Quebec, Canada: sanofi-aventis Canada Inc; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Effect of Intensive Blood-Glucose Control With Metformin on Complications in Overweight Patients With Type 2 Diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group,&rdquo; <i>Lancet</i>, 1998, 352(9131):854-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/9742977/pubmed\" target=\"_blank\" id=\"9742977\">9742977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ekpebegh CO, Coetzee EJ, van der Merwe L, et al, &quot;A 10-Year Retrospective Analysis of Pregnancy Outcome in Pregestational Type 2 Diabetes: Comparison of Insulin and Oral Glucose-Lowering Agents,&quot; <i>Diabet Med</i>, 2007, 24(3):253-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/17305787/pubmed\" target=\"_blank\" id=\"17305787\">17305787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elliott BD, Schenker S, Langer O, et al, &ldquo;Comparative Placental Transport of Oral Hypoglycemic Agents in Humans: A Model of Human Placental Drug Transfer,&rdquo; <i>Am J Obstet Gynecol</i>, 1994, 171(3):653-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/8092211/pubmed\" target=\"_blank\" id=\"8092211\">8092211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feig DS, Briggs GG, Kraemer JM, et al, &ldquo;Transfer of Glyburide and Glipizide Into Breast Milk,&rdquo; <i>Diabetes Care</i>, 2005, 28(8):1851-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/16043722/pubmed\" target=\"_blank\" id=\"16043722\">16043722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gabbe SG and Graves CR, &ldquo;Management of Diabetes Mellitus Complicating Pregnancy,&rdquo; <i>Obstet Gynecol</i>, 2003, 102(4):857-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/14551019/pubmed\" target=\"_blank\" id=\"14551019\">14551019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garratt KN, Brady PA, Hassinger NL, et al, &ldquo;Sulfonylurea Drugs Increase Early Mortality in Patients With Diabetes Mellitus After Direct Angioplasty for Acute Myocardial Infarction,&rdquo; <i>J Am Coll Cardiol</i>, 1999, 33(1):119-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/9935017/pubmed\" target=\"_blank\" id=\"9935017\">9935017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gavin JR 3rd, &ldquo;Glyburide: New Insights Into Its Effects on the Beta Cell and Beyond - Introduction,&rdquo; <i>Am J Med</i>, 1990, 89(2A):1S-2S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/2117383/pubmed\" target=\"_blank\" id=\"2117383\">2117383</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glynase PresTab [package insert]. New York, NY: Pharmacia &amp; Upjohn; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hebert MF, Ma X, Naraharisetti SB, et al, &quot;Are We Optimizing Gestational Diabetes Treatment With Glyburide? The Pharmacologic Basis For Better Clinical Practice,&quot; <i>Clin Pharmacol Ther</i>, 2009, 85(6):607-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/19295505/pubmed\" target=\"_blank\" id=\"19295505\">19295505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group,&rdquo; <i>Lancet</i>, 1998, 352(9131):837-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/9742976/pubmed\" target=\"_blank\" id=\"9742976\">9742976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson GF, Ramos GA, Ching JY, et al, &ldquo;Comparison of Glyburide and Insulin for the Management of Gestational Diabetes in a Large Managed Care Organization,&rdquo; <i>Am J Obstet Gynecol</i>, 2005, 193(1):118-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/16021069/pubmed\" target=\"_blank\" id=\"16021069\">16021069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in Ann Pharmacother. 2005;39(7-8):1373]. A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/15644481/pubmed\" target=\"_blank\" id=\"15644481\">15644481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joy S, Roman A, Istwan N, et al, &quot;The Effect of Maternal Obesity on Pregnancy Outcomes of Women With Gestational Diabetes Controlled With Diet Only, Glyburide, or Insulin,&quot; <i>Am J Perinatol</i>, 2012, 29(8):643-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/22644829/pubmed\" target=\"_blank\" id=\"22644829\">22644829</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26213555\"></a>Kelley KW, Carroll DG, Meyer A. A review of current treatment strategies for gestational diabetes mellitus. <i>Drugs Context</i>. 2015;4:212282.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/26213555/pubmed\" target=\"_blank\" id=\"26213555\">26213555</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirkman M, Briscoe VJ, Clark N, et al, &quot;Diabetes in Older Adults: A Consensus Report,&quot; <i>J Am Geriatr Soc</i>, 2012; doi: 10.1111/jgs.12035.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/23106132/pubmed\" target=\"_blank\" id=\"23106132\">23106132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitzmiller JL, Block JM, Brown FM, et al, &quot;Managing Preexisting Diabetes for Pregnancy: Summary of Evidence and Consensus Recommendations for Care,&quot; <i>Diabetes Care</i>, 2008, 31(5):1060-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/18445730/pubmed\" target=\"_blank\" id=\"18445730\">18445730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Langer O, Conway D, Berkus M, et al, &ldquo;A Comparison of Glyburide and Insulin in Women With Gestational Diabetes Mellitus,&rdquo; <i>N Engl J Med</i>, 2000, 343(16):1134-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/11036118/pubmed\" target=\"_blank\" id=\"11036118\">11036118</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Langer O, Yogev Y, Xenakis EM, et al, &quot;Insulin and Glyburide Therapy: Dosage, Severity Level of Gestational Diabetes, and Pregnancy Outcome,&quot; <i>Am J Obstet Gynecol </i>, 2005, 192(1):134-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/15672015/pubmed\" target=\"_blank\" id=\"15672015\">15672015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metzger BE, Buchanan TA, Coustan DR, et al, &quot;Summary and Recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus,&quot; <i>Diabetes Care</i>, 2007, 30(Suppl 2):S251-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/17596481/pubmed\" target=\"_blank\" id=\"17596481\">17596481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Myngheer N, Allegaert K, Hattersley A, et al. Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes. <i>Diabetes Care</i>. 2014;37(12):3333-3335.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/25231897/pubmed\" target=\"_blank\" id=\"25231897\">25231897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. <i>Am J Kidney Dis.</i> 2012;60(5):850-886. Erratum in: <i>Am J Kidney Dis</i>. 2013;61(6):1049. doi: 10.1053/j.ajkd.2012.07.005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/23067652/pubmed\" target=\"_blank\" id=\"23067652\">23067652</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pearson JG, &ldquo;Pharmacokinetics of Glyburide,&rdquo; <i>Am J Med</i>, 1985, 79(3B):67-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/3931464/pubmed\" target=\"_blank\" id=\"3931464\">3931464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pharmacy Quality Alliance. Use of high-risk medications in the elderly (HRM). http://pqaalliance.org/images/uploads/files/HRM2015.pdf. Published 2015. Accessed October 26, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/15461903 /pubmed\" target=\"_blank\" id=\"15461903 \">15461903 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwinghammer TL, Antal EJ, Kubacka RT, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Glyburide in Young and Elderly Nondiabetic Adults,&rdquo; <i>Clin Pharm</i>, 1991, 10(7):532-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/1907234/pubmed\" target=\"_blank\" id=\"1907234\">1907234</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/15242722/pubmed\" target=\"_blank\" id=\"15242722\">15242722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. <i>Semin Dial</i>. 2004;17(5):365-370.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/15461745/pubmed\" target=\"_blank\" id=\"15461745\">15461745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sonnenblick M and Shilo S, &ldquo;Glibenclamide Induced Prolonged Hypoglycaemia,&rdquo; <i>Age Ageing</i>, 1986, 15(3):185-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/3090865/pubmed\" target=\"_blank\" id=\"3090865\">3090865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/15373844/pubmed\" target=\"_blank\" id=\"15373844\">15373844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. <i>Diabetes Care</i>. 2014;37(10):2864-2883. doi: 10.2337/dc14-1296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/25249672/pubmed\" target=\"_blank\" id=\"25249672\">25249672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    UK Prospective Diabetes Study (UKPDS) Group, &quot;Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33),&quot; <i>Lancet</i>, 1998, 352(9131):837-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glyburide-glibenclamide-drug-information/abstract-text/9742976/pubmed\" target=\"_blank\" id=\"9742976\">9742976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/17596481</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8494 Version 235.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F176698\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F176699\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F176748\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F176703\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990695\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988016\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F176704\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F176673\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F176659\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F22123827\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F176678\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F176677\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725974\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F176756\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F176666\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F176681\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F176663\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F176743\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F176668\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F24257169\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F176684\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F1699343\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F176685\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F176671\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F176674\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F176662\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F176680\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F176683\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F176686\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8494|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=glyburide-glibenclamide-patient-drug-information\" class=\"drug drug_patient\">Glyburide (glibenclamide): Patient drug information</a></li></ul></div></div>","javascript":null}